Martine Darwish

Ms. Martine Darwish

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EHEmily Holz
Emily Holz
MDMartine Darwish
Martine Darwish
DTDevin B. Tesar
Devin B. Tesar
WSWhitney Shatz-Binder
Whitney Shatz-Binder
Over the past few decades, the complexity of molecular entities being advanced for therapeutic purposes has continued to evolve. A main propellent fueling innovation is the perpetual mandate within the pharmaceutical industry to meet the needs of novel disease areas and/or delivery challenges. As new mechanisms of action are uncovered, and as our understanding of existing mechanisms grows, the properties that are required and/or leveraged to enable therapeutic development continue to expand. One rapidly evolving area of interest is that of chemically enhanced peptide and protein therapeutics. While a variety of conjugate molecules such as antibody–drug conjugates, peptide/protein–PEG conjugates, and protein conjugate vaccines are already well established, others, such as antibody–oligonucleotide conjugates and peptide/protein conjugates using non-PEG polymers, are newer to clinical development. This review will evaluate the current development landscape of protein-based chemical conjugates with special attention to considerations such as modulation of pharmacokinetics, safety/tolerability, and entry into difficult to access targets, as well as bioavailability. Furthermore, for the purpose of this review, the types of molecules discussed are divided into two categories: (1) therapeutics that are enhanced by protein or peptide bioconjugation, and (2) protein and peptide therapeutics that require chemical modifications. Overall, the breadth of novel peptide- or protein-based therapeutics moving through the pipeline each year supports a path forward for the pursuit of even more complex therapeutic strategies.

11 April 2021 in Protein Science
Verified
Journal Article
Closed access
PDF file
MDMartine Darwish
Martine Darwish
SWSara Wichner
Sara Wichner
JLJenny Li
Jenny Li
JCJiun Chiun Chang
Jiun Chiun Chang
CTChristine Tam
Christine Tam
CBCraig Blanchette
Craig Blanchette

9 August 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
YKYu Kong
Yu Kong
CRChris Rose
Chris Rose
ACAshley A. Cass
Ashley A. Cass
MDMartine Darwish
Martine Darwish
SLSteve Lianoglou
Steve Lianoglou
HCHaiyin Chen-Harris
Haiyin Chen-Harris
Profound loss of DNA methylation is a well-recognized hallmark of cancer. Given its role in silencing transposable elements (TEs), we hypothesized that extensive TE expression occurs in tumors with highly demethylated DNA. We developed REdiscoverTE, a computational method for quantifying genome-wide TE expression in RNA sequencing data. Using The Cancer Genome Atlas database, we observed increased expression of over 400 TE subfamilies, of which 262 appeared to result from a proximal loss of DNA methylation. The most recurrent TEs were among the evolutionarily youngest in the genome, predominantly expressed from intergenic loci, and associated with antiviral or DNA damage responses. Treatment of glioblastoma cells with a demethylation agent resulted in both increased TE expression and de novo presentation of TE-derived peptides on MHC class I molecules. Therapeutic reactivation of tumor-specific TEs may synergize with immunotherapy by inducing both inflammation and the display of potentially immunogenic neoantigens. One Sentence Summary: Transposable element expression in tumors is associated with increased immune response and provides tumor-associated antigens

26 October 2026 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
JLJoyce Liu
Joyce Liu
SCShu Chen
Shu Chen
YCYi-Chen Chen
Yi-Chen Chen
YCYusi Cui
Yusi Cui
MDMartine Darwish
Martine Darwish
DZDonglu Zhang
Donglu Zhang